Liquidia’s (LQDA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Liquidia (NASDAQ:LQDA) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $29.00 price objective on the stock. HC Wainwright also issued estimates for Liquidia’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

A number of other research analysts have also recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Liquidia in a research note on Thursday, January 9th. Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $26.63.

Liquidia Stock Performance

LQDA opened at $15.12 on Thursday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -9.28 and a beta of 0.07. The stock’s 50 day moving average price is $14.79 and its 200-day moving average price is $12.20. Liquidia has a one year low of $8.26 and a one year high of $16.92.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, analysts predict that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 22,343 shares of the firm’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $263,200.54. Following the completion of the transaction, the chief executive officer now owns 1,019,177 shares in the company, valued at $12,005,905.06. This trade represents a 2.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rajeev Saggar sold 6,249 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $73,613.22. Following the sale, the insider now directly owns 270,388 shares in the company, valued at $3,185,170.64. This represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,245 shares of company stock valued at $843,326 over the last quarter. 30.10% of the stock is owned by corporate insiders.

Institutional Trading of Liquidia

Institutional investors have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of Liquidia during the 4th quarter valued at approximately $59,000. Summit Investment Advisors Inc. raised its position in Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after purchasing an additional 1,719 shares during the period. Walleye Trading LLC raised its position in Liquidia by 54.7% in the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after purchasing an additional 4,670 shares during the period. D. E. Shaw & Co. Inc. purchased a new stake in Liquidia in the fourth quarter valued at approximately $142,000. Finally, EntryPoint Capital LLC purchased a new stake in Liquidia in the fourth quarter valued at approximately $154,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).